Chris Molloy (IDBS) spoke to Bioanalysis Zone in September 2011.
Could you tell Bioanalysis Zone a little about your career to date and how you ended up in your current role?
My career started in cell biology/biochemistry with GlaxoSmithKline in 1990 at the very beginning of the drive to industrialize R&D. Through 14 years with the company, I moved across many therapeutic and scientific disciplines from cancer and respiratory disease to Alzheimer’s and a range of enzyme-based therapeutic targets, working internally and in collaboration with biotech. As the company expanded, I became increasingly responsible for preclinical business improvement projects, coordinating IT and automation portfolios across screening and lead optimization, worldwide, to drive efficiency and productivity. In 2004, I moved to Singapore, China, as COO of MerLion Pharmaceuticals, an award-winning Asian-headquartered, international R&D biotech focusing on natural product research and the successful clinical development of anti-infectives. I joined IDBS in 2008 as VP of Corporate Development.